Clinical Trials
The ultimate goal in translational medicine is to test and validate new therapeutic options in humans and to advance appropriate tools for tailored treatment. Therefore, a major aim of the DZL is to promote and enable the progress of early clinical trials, fostering these approaches.
DZL aims to facilitate innovative investigator initiated studies (IITs) in lung diseases. A particular focus of the DZL are innovative Phase IIa IITs. These might be studies in wellcharacterized subgroups of patients, to explore the option of personalized medicine (for example, in oncology, aiming to match patients with molecularly defined alterations of the tumour to specific treatments). These studies are ideally combined with predictive diagnostics approaches.
Furthermore, studies where industry is less interested or which explore new indications of already authorized or off-patent medicinal products, are in the focus of the DZL.
Innovative science can often lead in unexpected directions. In order to be able to respond to new findings in the field and translate those findings as quickly as possible to positive outcomes for patients, a portion of the DZL budget was set aside for innovative clinical trials.
CHANGE-MRI (CTEPH DIAGNOSIS Europe - MRI) Phase III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH
Coorditating Investigator: Prof. Dr. Jens Vogel-Claussen
Cooperating Partners: BREATH, CPC, TLRC, UGMLC